Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NTGN

Neon Therapeutics (NTGN) Stock Price, News & Analysis

Neon Therapeutics logo

About Neon Therapeutics Stock (NASDAQ:NTGN)

Key Stats

Today's Range
$3.07
$3.07
50-Day Range
$2.77
$3.07
52-Week Range
$0.88
$6.25
Volume
N/A
Average Volume
516,108 shs
Market Capitalization
$88.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive NTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTGN Stock News Headlines

BCYC Bicycle Therapeutics plc
NTGN_old Historical Data
The Tesla Trade Is Back In Business
If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.
NBCO Neon Bloom, Inc.
See More Headlines

NTGN Stock Analysis - Frequently Asked Questions

Neon Therapeutics Inc (NASDAQ:NTGN) released its earnings results on Monday, March, 2nd. The company reported ($0.63) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.03.

Neon Therapeutics (NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neon Therapeutics investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Sorrento Therapeutics (SRNE), Aduro Biotech (ADRO) and Altimmune (ALT).

Company Calendar

Last Earnings
3/02/2020
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:NTGN
CIK
N/A
Fax
N/A
Employees
102
Year Founded
N/A

Profitability

Net Income
$-79,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.50 per share

Miscellaneous

Free Float
N/A
Market Cap
$88.93 million
Optionable
Not Optionable
Beta
-0.81
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NASDAQ:NTGN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners